Dual Task Gait Performance in Pediatric Oncology Patients

Afyonkarahisar Health Sciences University40 enrolled

Overview

Cancer incidence, which is recognized as the leading cause of death in children worldwide, is gradually increasing. Most studies on children who survive cancer show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, gait and cognitive skills. Therefore, dual task gait performance, in which cognitive and motor tasks are performed simultaneously, may be affected in pediatric oncology patients. The aim of this study is to compare gait performance in single and dual task conditions in pediatric oncology patients with healthy controls.

Cancer incidence, which is recognized as the leading cause of death in children worldwide, is gradually increasing. About 300,000 children aged 0 to 19 are diagnosed with cancer each year, according to the international study where the International Agency for Research on Cancer collected data on neoplasms (malignant and non-malignant) diagnosed in individuals under 20 years of age between 2001-2010. Most studies on children who survive cancer show that the disease and its treatment have side effects and long-term late effects on the musculoskeletal system, physical function, gait and cognitive skills. According to the study of Beulertz et al. (2016), active ankle dorsiflexion limitation, gait disturbances and decrease in walking efficiency were observed in all pediatric oncology patients, which have an important role in walking, not limited to children with bone tumors and central nervous system tumors.Intensive chemotherapy (eg methotrexate) and the use of radiation are thought to cause damage to cortical and subcortical white matter, resulting in late effects. Symptoms consistent with attention deficit disorder and mental processing speed, working memory, executive function and memory deficits put cancer survivors at an intellectual and academic disadvantage. Therefore, dual task gait performance, in which cognitive and motor tasks are performed simultaneously, may be affected in pediatric oncology patients. The aim of this study is to compare gait performance in single and dual task conditions in pediatric oncology patients with healthy controls.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Pediatric Cancer

Interventions

Gait assessment (single)OTHER

The single walk will be evaluated with a 10-meter walking test and a G-Walk portable device.

Dual task gait assessment (motor+motor)OTHER

The dual task gait, 10-meter walking test and a motor (carrying a full water glass) will be combined with the task and evaluated with the G-Walk portable device.

Dual tak gait assessment (motor+cognitive)OTHER

The dual task gait will be combined with a 10-meter walking test and a cognitive (1-back test) task and evaluated with the G-Walk portable device.

Eligibility

Sex: ALLMin age: 6 YearsMax age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Healthy control group: * Being in the age range of 6-18, * To be physically, cognitively and mentally healthy, * Open to communication enough to understand questions, * Speaking and understanding Turkish, * Approval has been obtained from the child and his / her family for the study and who agrees to participate in the study, Case group: * Able to walk alone without any walking aid, * Open to communication enough to understand questions, * Speaking and understanding Turkish, * Approval has been obtained from the child and his / her family for the study and who agrees to participate in the study, * Children between the ages of 6-18 will be included in the study Exclusion Criteria: Healthy control group: * Any orthopedic or neurological impairment that would prevent walking; * Having any mental disability that prevents cognitive task Case group: * Staying in an isolated room or having risk of infection (neutropenic, etc.), * Any orthopedic or neurological impairment that could prevent walking; * Having any mental disability that prevents cognitive task, * Individuals with malignant hypertension or unstable heart disease (eg congestive heart failure) will not be included in the study.

Locations (1)

Emel Taşvuran Horata

Afyonkarahisar, Turkey (Türkiye)

RECRUITING

Outcomes

Primary Outcomes

gait speed

Gait speed is the time one takes to walk a specified distance on level surfaces over a short distance.

Time frame: 20 minutes

cadence

Cadence is the rate at which a person walk, expressed in steps per minute. The average cadence is 100 - 115 steps/min.

Time frame: 20 minutes

stride length

Stride length is defined as the distance between successive ground contacts of the same foot.

Time frame: 20 minutes

Central Contacts

EMEL TAŞVURAN HORATA, PhD

CONTACT

05547759663 ethorata@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.